Reassuring order intake and strong trading momentum Yesterday, VOQUZ published reassuring 2023 order intake figures, pointing towards improved operations in the second half of the year. Total order intake increased by 11.5% yoy to € 5.5m with recurring orders accounting for a solid 58% (€ 3.2m). The share of product related sales sl [ … ]

Operational turnaround in full swing – Added to Alpha List; chg. While the company has not been on the radar of most investors due to rather underwhelming operating performances in recent years, efficiency measures, which have been imposed lately as well as the reorganization of the topand C-level management are starting to bear fruit, t [ … ]

First Berlin Equity Research hat ein Research Update zu Klondike Gold Corp. (ISIN: CA4989033010) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von CAD 0,75. Zusammenfassung: Klondike Gold veröffentlichte die Bohrergebnisse der Zone Standard, die die Reihe der auffälligen [ … ]

Annual portfolio revaluation in line with expectations Yesterday, DEMIRE published an ad-hoc following a draft valuation from Savills. The external surveyor is currently performing the annual valuation of DEMIRE’s investment properties as of 31 December ’23. Based on the draft, the company currently expects that the fair value of th [ … ]

Storytelling-based value and growth play for 2024 With its storytelling-based retail approach and inspiration-driven revenue generation, Westwing is a unique play on the growing online penetration in the home and living segment. The latter still stands at 25% for fashion or >35% for electronics. Its focus on curated home furnishings along wi [ … ]

The crypto markets, in particular Ethereum (ETH), Bitcoin (BTC) and The Graph (GRT), have gained significantly since October 2023. The positive development reflects the approval of Bitcoin spot ETFs, the hope for the approval of Ethereum spot ETFs and the upcoming Bitcoin halving in April 2024. coinIX is benefiting in the short term from its significant holdings of BTC, ETH and GRT. Furthermore, Moritz Schildt has taken over as CEO of coinIX, bringing proven management and blockchain expertise. An update of AlsterResearch’s NAV valuation model with current prices results in a new fair value per share of EUR 3.08 (old: EUR 2.36), and thus a further upside potential of more than 30%. BUY. The full update can be downloaded under research-hub.de/companies/coinIX%20GmbH%20&%20Co%20KGaA

A new CEO to kick off the year Topic: LION announced to have a singed a highly qualified successor for the current CEO, which is leaving at the end of January. Following LION‘s major transformation last year, the company looks poised for strong growth. At the end of November, LION announced the departure of its CEO Winfried Buss end of  [ … ]

First Berlin Equity Research has published a research update on Cardiol Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera reiterated his BUY rating and maintained his USD 3.60 price target. Abstract: Cardiol Therapeutics (Cardiol) has completed >50% of patient recruitment for CardiolRx's two lead indications, acute myocarditi [ … ]

InVision entered into a delisting agreement back in December. The bidder Acme 42, owned by CEO and founder Peter Bollenbeck and other close associates of InVision, published yesterday the offer documents. Accordingly, Acme 42 is offering a cash price of EUR 6.09 per share. Trading in the shares will be discontinued shortly and may only be possible via the Hamburg Stock Exchange, which has voluntarily taken over the pricing and trading in comparable cases. Whether this will also be the case for InVision remains to be seen. AlsterResearch’s analysts therefore confirm their view to accept the offer or to sell the shares via the stock exchange, depending on the current share price. SELL. The full update can be downloaded under https://www.research-hub.de/companies/research/InVision%20AG

BASF faces challenges in FY23/Q4 with weaker-than-expected results due to reduced demand and increased costs, influenced by a global economic downturn and rising energy prices related to the war in Ukraine. FY23 sales of EUR 68.9bn fell 20% yoy and hence below consensus and AlsterResearch forecasts. Q4 results (-9% yoy), however, indicate a slower contraction, raising optimism for a return to growth in FY24. EBIT before special items dropped 45% to EUR 3.8bn, missing targets and consensus estimates. BASF plans to cut costs further, focusing on Europe, after already reducing capex. Despite improved operating cash flows (EUR 8.1bn), FY23 profitability at EUR 225m falls short of expectations. Strategic moves, including subsidiary sales, aim to alleviate financial pressures. Despite challenges, AlsterResearch’s analysts maintain their BUY rating with unchanged PT of EUR 58.50, anticipating potential growth in FY24E. The full update can be downloaded under https://www.research-hub.de/companies/BASF%20SE